Strs Ohio Cuts Stake in Moderna, Inc. (NASDAQ:MRNA)

Strs Ohio cut its position in Moderna, Inc. (NASDAQ:MRNA) by 4.0% in the 4th quarter, Holdings Channel reports. The institutional investor owned 89,105 shares of the company’s stock after selling 3,689 shares during the quarter. Strs Ohio’s holdings in Moderna were worth $8,861,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in MRNA. Bay Colony Advisory Group Inc d b a Bay Colony Advisors raised its holdings in Moderna by 6.5% in the 4th quarter. Bay Colony Advisory Group Inc d b a Bay Colony Advisors now owns 2,459 shares of the company’s stock worth $245,000 after acquiring an additional 151 shares during the last quarter. Conning Inc. purchased a new position in shares of Moderna in the fourth quarter worth $207,000. Vontobel Holding Ltd. raised its stake in shares of Moderna by 6.8% in the fourth quarter. Vontobel Holding Ltd. now owns 55,799 shares of the company’s stock worth $5,549,000 after purchasing an additional 3,576 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. lifted its holdings in shares of Moderna by 16.6% during the fourth quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,081,869 shares of the company’s stock valued at $107,592,000 after purchasing an additional 154,112 shares in the last quarter. Finally, Louisiana State Employees Retirement System purchased a new stake in shares of Moderna during the fourth quarter valued at $5,012,000. Institutional investors own 75.33% of the company’s stock.

Moderna Trading Down 0.3 %

Moderna stock opened at $103.44 on Thursday. Moderna, Inc. has a 12-month low of $62.55 and a 12-month high of $144.93. The firm has a market capitalization of $39.61 billion, a price-to-earnings ratio of -8.34 and a beta of 1.62. The firm has a 50 day moving average of $100.10 and a 200 day moving average of $93.52. The company has a current ratio of 3.42, a quick ratio of 3.36 and a debt-to-equity ratio of 0.04.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings data on Thursday, February 22nd. The company reported $0.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.78) by $1.33. Moderna had a negative net margin of 68.84% and a negative return on equity of 10.23%. The firm had revenue of $2.80 billion during the quarter, compared to analysts’ expectations of $2.53 billion. During the same period in the prior year, the company posted $3.61 earnings per share. The company’s revenue for the quarter was down 44.9% compared to the same quarter last year. As a group, research analysts predict that Moderna, Inc. will post -7.51 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the company. Oppenheimer raised Moderna from a “market perform” rating to an “outperform” rating and set a $142.00 target price for the company in a research report on Tuesday, January 2nd. Needham & Company LLC restated a “hold” rating on shares of Moderna in a research report on Thursday, April 11th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $125.00 target price on shares of Moderna in a research report on Tuesday, April 9th. Royal Bank of Canada reissued an “outperform” rating and set a $125.00 price target on shares of Moderna in a report on Thursday, March 28th. Finally, Canaccord Genuity Group lifted their price objective on Moderna from $82.00 to $91.00 and gave the stock a “hold” rating in a report on Friday, February 23rd. Two analysts have rated the stock with a sell rating, nine have given a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, Moderna currently has an average rating of “Hold” and an average price target of $126.49.

Insiders Place Their Bets

In other news, CFO James M. Mock sold 647 shares of the business’s stock in a transaction dated Thursday, February 29th. The stock was sold at an average price of $94.57, for a total value of $61,186.79. Following the transaction, the chief financial officer now directly owns 4,300 shares in the company, valued at $406,651. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In related news, CFO James M. Mock sold 647 shares of Moderna stock in a transaction that occurred on Thursday, February 29th. The stock was sold at an average price of $94.57, for a total transaction of $61,186.79. Following the sale, the chief financial officer now owns 4,300 shares of the company’s stock, valued at approximately $406,651. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, President Stephen Hoge sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, April 15th. The stock was sold at an average price of $105.02, for a total value of $1,575,300.00. Following the completion of the transaction, the president now directly owns 1,486,241 shares in the company, valued at $156,085,029.82. The disclosure for this sale can be found here. In the last quarter, insiders sold 94,954 shares of company stock worth $9,983,276. Corporate insiders own 15.70% of the company’s stock.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.